Security key
36269B105
- Security type / class
- Equity / COM
- Total 13F shares
- 98,806
- Total 13F value
- $196,654
- Share change
- +21,000
- SEC-reported price per share
- $2.03
- Number of holders
- 4
- Value change
- +$42,285
- Number of buys
- 2
Report period
Q2 2026
Institutions
4
Top holders
4
GANX full security history
Ownership snapshot
Full 13F holder table
Previous quarter: Q1 2026
Gain Therapeutics, Inc. SEC filings
Gain Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 36269B105
Recent filing periods:
Ownership snapshot
Top reported holders of GANX - Gain Therapeutics, Inc. - COM (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
MARSHALL WACE, LLP
Disclosed value leader
MARSHALL WACE, LLP
Comparable rows
0/15
Latest evidence
31 Mar 2026
13F
3/4/5
Highest disclosed value: $3,433,389
15 rows are not safely comparable across share classes.
Showing 1-6 of 15 holder rows.
Quick read
MARSHALL WACE, LLP has the largest disclosed position value at $3.43M.
0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens MARSHALL WACE, LLP's linked filing trail.
Disclosed position value
Top 5
MARSHALL WACE, LLP
$3.43M
Potomac Capital Management, Inc.
$1.96M
Eric I. Richman
$1.17M
JONES FINANCIAL COMPANIES LLLP
$1.16M
Cambridge Investment Research Adv...
$1.1M
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| MARSHALL WACE, LLP |
13F
Company
|
—
class O/S missing
|
$3,433,389
1,769,788 shares
|
— | 31 Mar 2026 |
| Potomac Capital Management, Inc. |
13F
Company
|
—
class O/S missing
|
$1,956,684
1,008,600 shares
|
— | 31 Mar 2026 |
| Eric I. Richman |
3/4/5
Director
|
—
mixed-class rows
|
$1,174,903
319,458 shares
mixed-class rows
|
— | 24 Jun 2025 |
| JONES FINANCIAL COMPANIES LLLP |
13F
Company
|
—
class O/S missing
|
$1,155,855
631,615 shares
|
— | 31 Mar 2026 |
| Cambridge Investment Research Advisors, Inc. |
13F
Company
|
—
class O/S missing
|
$1,103,000
568,645 shares
|
— | 31 Mar 2026 |
| DME Capital Management, LP |
13F
Company
|
—
class O/S missing
|
$1,098,292
566,130 shares
|
— | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
4
Shares
98,806
Rows available
4
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2026 vs Q1 2026 Across Filers
Q1 2026 holders
42
Q2 2026 holders
4
Holder diff
-38
| Investor | Q1 2026 Shares | Q2 2026 Shares | Share Diff | Share Chg % | Q1 2026 value | Q2 2026 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend